276 related articles for article (PubMed ID: 29673809)
21. Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience.
Haché M; Swoboda KJ; Sethna N; Farrow-Gillespie A; Khandji A; Xia S; Bishop KM
J Child Neurol; 2016 Jun; 31(7):899-906. PubMed ID: 26823478
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
[TBL] [Abstract][Full Text] [Related]
23. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
[TBL] [Abstract][Full Text] [Related]
24. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen.
Aragon-Gawinska K; Daron A; Ulinici A; Vanden Brande L; Seferian A; Gidaro T; Scoto M; Deconinck N; Servais L;
Dev Med Child Neurol; 2020 Mar; 62(3):310-314. PubMed ID: 31799720
[TBL] [Abstract][Full Text] [Related]
25. Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.
Zuluaga-Sanchez S; Teynor M; Knight C; Thompson R; Lundqvist T; Ekelund M; Forsmark A; Vickers AD; Lloyd A
Pharmacoeconomics; 2019 Jun; 37(6):845-865. PubMed ID: 30714083
[TBL] [Abstract][Full Text] [Related]
26. A new respiratory scoring system for evaluation of respiratory outcomes in children with spinal muscular atrophy type1 (SMA1) on SMN enhancing drugs.
Edel L; Grime C; Robinson V; Manzur A; Abel F; Munot P; Ridout D; Scoto M; Muntoni F; Chan E
Neuromuscul Disord; 2021 Apr; 31(4):300-309. PubMed ID: 33752934
[TBL] [Abstract][Full Text] [Related]
27. Long-term benefits of nusinersen in a child affected by cystic fibrosis and spinal muscular atrophy type 1.
Bruno G; Donnarumma B; Inverardi A; Buonpensiero P; Sepe A; Tosco A; Raia V; Varone A
Pediatr Pulmonol; 2021 Jun; 56(6):1806-1808. PubMed ID: 33684256
[No Abstract] [Full Text] [Related]
28. Clinical Outcomes in Patients with Spinal Muscular Atrophy Type 1 Treated with Nusinersen.
de Holanda Mendonça R; Jorge Polido G; Ciro M; Jorge Fontoura Solla D; Conti Reed U; Zanoteli E
J Neuromuscul Dis; 2021; 8(2):217-224. PubMed ID: 33459657
[TBL] [Abstract][Full Text] [Related]
29. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
30. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
Chacko A; Sly PD; Gauld L
Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
[No Abstract] [Full Text] [Related]
31. Resolution of skin necrosis after nusinersen treatment in an infant with spinal muscular atrophy.
Salmin F; Albamonte E; Morettini V; Gagliano N; Mercuri E; Sansone VA
Muscle Nerve; 2019 Jun; 59(6):E42-E44. PubMed ID: 30811610
[No Abstract] [Full Text] [Related]
32. Nusinersen improved respiratory function in spinal muscular atrophy type 2.
Tanaka R; Fukushima F; Motoyama K; Kobayashi C; Izumi I
Pediatr Int; 2021 Aug; 63(8):973-974. PubMed ID: 34245199
[No Abstract] [Full Text] [Related]
33. Intrathecal delivery of nusinersen in individuals with complicated spines.
Cartwright MS; Ward ZT; White EP; West TG
Muscle Nerve; 2020 Jul; 62(1):114-118. PubMed ID: 32319101
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound-guided cervical puncture for nusinersen administration in adolescents.
Ortiz CB; Kukreja KU; Lotze TE; Chau A
Pediatr Radiol; 2019 Jan; 49(1):136-140. PubMed ID: 30167764
[TBL] [Abstract][Full Text] [Related]
35. Treating adults with spinal muscular atrophy with nusinersen.
Farrar MA; Kiernan MC
J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1139. PubMed ID: 32917825
[No Abstract] [Full Text] [Related]
36. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience.
Chen KA; Widger J; Teng A; Fitzgerald DA; D'Silva A; Farrar M
Paediatr Respir Rev; 2021 Sep; 39():54-60. PubMed ID: 33129670
[TBL] [Abstract][Full Text] [Related]
37. Reply to Chacko
LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
Am J Respir Crit Care Med; 2020 Mar; 201(5):624-626. PubMed ID: 31747301
[No Abstract] [Full Text] [Related]
38. Transforaminal intrathecal delivery of nusinersen using cone-beam computed tomography for children with spinal muscular atrophy and extensive surgical instrumentation: early results of technical success and safety.
Weaver JJ; Natarajan N; Shaw DWW; Apkon SD; Koo KSH; Shivaram GM; Monroe EJ
Pediatr Radiol; 2018 Mar; 48(3):392-397. PubMed ID: 29130140
[TBL] [Abstract][Full Text] [Related]
39. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal catheter and port placement for nusinersen infusion in children with spinal muscular atrophy and spinal fusion.
Shashi KK; Stone SSD; Berde CB; Padua HM
Pediatr Radiol; 2021 Dec; 51(13):2588-2595. PubMed ID: 34254153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]